Articles tagged with: Imnovid
News»

The year 2013 is likely to be remembered as a very good year when it comes to research related to multiple myeloma.
Previous years have witnessed research shedding new light on existing myeloma therapies, as well as additional research about potential new therapies.
But, in the past, most of the important new therapies that were being researched were from existing classes of therapy, making them less likely to offer dramatic improvements in the treatment of the disease.
In 2013, not only was there more research about existing therapies, and more research about …
News»

Pomalyst is now approved in Canada for the treatment of certain patients with multiple myeloma.
Specifically, Health Canada approved Pomalyst (pomalidomide, Imnovid) for use in combination with dexamethasone (Decadron) in patients with multiple myeloma for whom both Revlimid (lenalidomide) and Velcade (bortezomib) have failed, who have received at least two prior treatment regimens, and who have demonstrated disease progression on their last therapy.
Health Canada approved Pomalyst on January 20, but the approval was first announced this morning.
Celgene (NASDAQ: CELG), the company that developed and markets Pomalyst, expects Pomalyst …
Press Releases»
POMALYST Is A New Option For Patients Whose Disease Has Progressed Despite Treatment With Available Therapies
Mississauga, Ontario (Press Release) - Health Canada has approved POMALYST™ oral therapy (pomalidomide capsules) in combination with dexamethasone, for patients with multiple myeloma for whom both lenalidomide and bortezomib have failed, who have received at least two prior treatment regimens and have demonstrated disease progression on their last regimen. Until POMALYST, there have been few options for patients whose disease has progressed despite being treated with traditional therapies. Treatment with POMALYST has been shown to improve rates of overall survival and extend progression-free survival in patients who no longer respond to lenalidomide …
News»

At the 2013 annual meeting of the American Society of Hematology (ASH), which took place in December, there were many oral and poster presentations about Pomalyst, the newest drug approved in the United States and Europe for the treatment of multiple myeloma.
Many of the presentations were about studies of Pomalyst (pomalidomide, Imnovid) and dexamethasone (Decadron) in combination with a third drug, such as Velcade (bortezomib), Kyprolis (carfilzomib), clarithromycin (Biaxin), cyclophosphamide (Cytoxan), or Doxil (doxorubicin liposomal), for relapsed and refractory myeloma.
Several of …
News»

This Monday was the third day of the 2013 American Society of Hematology (ASH) annual meeting, which was held in New Orleans.
More than any other day of the conference, Monday was packed with important myeloma presentations, from 7:00 in the morning until almost 8:00 in the evening.
This ASH update will summarize the oral presentation sessions about treatment-related myeloma studies that were held Monday morning. An ASH update that was published on Wednesday focused on the sessions that were held Monday afternoon and evening.
Monday morning started with three simultaneous …
News»

Monday was the third day of this year’s meeting of the American Society of Hematology (ASH). The day was filled with oral presentation sessions from early in the morning until into the evening.
In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon. The topics of these presentations ranged from the biology of myeloma to treatment options for newly diagnosed, relapsed and refractory, and older patients.
This ASH update highlights most of the oral …
News»

Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.
As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.
Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.
One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are considered particularly important studies.
The myeloma study included in this session was …